1 Supplementary appendix Seroprevalence of anti - SARS - CoV - 2 antibodies and cross - variant neutralization capacity after the Omicron BA . 2 wave in Geneva , Switzerland : a population - based study Mar√≠a - Eugenia Zaballa , Javier Perez - Saez , Carlos de Mestral , Nick Pullen , Julien Lamour , Priscilla Turelli , Charl√®ne Raclot , H√©l√®ne Baysson , Francesco Pennacchio , Jennifer Villers , Julien Duc , Viviane Richard , Roxane Dumont , Claire Semaani , Andrea Jutta Loizeau , Cl√©ment Graindorge , Elsa Lorthe , Jean - Fran√ßois Balavoine , Didier Pittet , Manuel Schibler , Nicolas Vuilleumier , Fran√ßois Chappuis , Omar Kherad , Andrew S . Azman , Klara M . Posfay - Barbe , Laurent Kaiser , Didier Trono , Silvia Stringhini , Idris Guessous , on behalf of the Specchio - COVID19 study group 2 Supplementary information S1 . Study sample selection and questions given to participants that were used in the present study Our participant recruitment method included inviting new participants as well as returning participants . To recruit new participants , we obtained from the cantonal population registry in Geneva , Switzerland , a list of randomly selected individuals per age group based on the age distribution of the general population of Geneva , Switzerland , weighted by the estimated participation rate per age group ( Office cantonal de la population et des migrations ; https : / / www . ge . ch / organisation / office - cantonal - population - migrations - ocpm ) . Children and teenagers ( aged < 18 years ) were invited to participate with members of their household . As a complement to this sample , participants from at least one of our previous seroprevalence studies , 1 ‚Äì 3 themselves obtained with the same procedure described above , were randomly drawn and invited to participate again . With the aim of not amplifying participation bias , the selection among former participants was done stratifying by age , sex , and education level in order to mimic the Geneva population ' s distribution . Missing education data in this selection was inferred assuming a similar distribution as the rest of the sample . Question Answer choices What is your date of birth ? day / month / year What is your sex ? Male / Female / Other Vaccination Have you received the first dose of the vaccine against COVID - 19 ? Yes / No Have you received the second dose of the vaccine against COVID - 19 ? Yes / No If yes , date ( month / year ) Have you received the ‚Äúbooster‚Äù dose of the vaccine against COVID - 19 ? Yes / No If yes , date ( day / month / year ) Since the beginning of the pandemic , have you had a confirmed COVID - 19 diagnosis , meaning having a positive COVID - 19 test from a nasal / throat swab , either RT - PCR or rapid antigenic test , including self - test ? Yes / No If yes , date ( month / year ) [ for each positive test ] Educational level What is the highest level diploma / certification that you have obtained ? - None - Primary school and / or orientation cycle - Secondary education ‚Äì Maturit√© / High School - Professional training ‚Äì Certified apprenticeship ( CFC ) - Professional training ‚Äì Non - certified apprenticeship - Professional training ‚Äì Higher professional degrees ( post - CFC ) - Tertiary education ‚Äì Bachelor / Master degree - Tertiary education ‚Äì Doctorate / PhD degree - Other 3 Supplementary information S2 . Overview of Statistical Frameworks S2 . 1 Antibody presence and origin Our first aim was to infer the proportion of the population having any antibodies against SARS - CoV - 2 , as well as the proportion of those who acquired antibodies through natural infection as opposed to vaccination - only . We did so following our previous work by modelling jointly the antibody response measured by the Roche - N and Roche - S immunoassays together with participants‚Äô responses to a vaccination questionnaire . 3 Population - level estimates of antibody seroprevalence of any or infection origin were then obtained using demographic statistics on the population of Geneva , as well as official statistics on age - specific vaccination rates in the population ( Table S2 ) . Post - stratification therefore allows us to correct for the demographic biases of our sample . We disentangled natural infection from vaccination antibody responses using the fact that the only available vaccines in Switzerland to date‚Äîthe mRNA - 1273 from Moderna / US NIAID , 4 the mRNA - BNT162b2 / Comirnaty from Pfizer / BioNTech , 5 and the Janssen Ad26 . COV2 . S COVID - 19 vaccine 6 ‚Äîelicit a response exclusively to the S protein of SARS - CoV - 2 , as opposed to natural infections which typically elicit a response to both the N and S virus proteins . We expanded previous Bayesian modelling frameworks used for seroprevalence estimates that account for demographic parameters ( sex and age ) , test performance and household infection clustering . 1 , 2 The main difference with our previous study is that here we considered that the probability of vaccination is independent from the probability of infection , which was not the case by June - July 2021 due to Geneva‚Äôs vaccination policy . 3 S2 . 1 . 1 Multinomial response model We modeled the Roche - S and Roche - N tests results for participant ùëñ , ùë• ùëñ , consisting of one of four possible outcome combinations [ ùëõ ùëÜ + ùëÅ + , ùëõ ùëÜ ‚àí ùëÅ + , ùëõ ùëÜ + ùëÅ ‚àí , ùëõ ùëÜ ‚àí ùëÅ ‚àí ] ( + indicates antibody presence ; ‚àí indicates absence ) with ùë• ùëñ ‚àà { [ 1 , 0 , 0 , 0 ] , [ 0 , 1 , 0 , 0 ] , [ 0 , 0 , 1 , 0 ] , [ 0 , 0 , 0 , 1 ] } using a multinomial distribution parametrized by parameter vector ùúã ùëñ = [ ùúã ùëñ + + , ùúã ùëñ‚àí + , ùúã ùëñ + ‚àí , ùúã ùëñ‚àí‚àí ] , where ùúã ùëôùëö is the probability of having Roche - S test result ùëô and Roche - N result ùëö , accounting for both the underlying probability of each antibody status ùëù ¬± / ¬± , and test sensitivity , ùúÉ + and specificity , ùúÉ ‚àí : ùë• ùëñ ~ Multinomial ( ùúã ùëñ ) ùúã ùëñ + + = ùúÉ ùëÜ + ùúÉ ùëÅ + ùëù ùëñ + + + ( 1 ‚àí ùúÉ ùëÜ‚àí ) ùúÉ ùëÅ + ùëù ùëñ‚àí + + ùúÉ ùëÜ + ( 1 ‚àí ùúÉ ùëÅ‚àí ) ùëù ùëñ + ‚àí + ( 1 ‚àí ùúÉ ùëÜ‚àí ) ( 1 ‚àí ùúÉ ùëÅ‚àí ) ùëù ùëñ‚àí‚àí , ùúã ùëñ‚àí + = ( 1 ‚àí ùúÉ ùëÜ + ) ùúÉ ùëÅ + ùëù ùëñ + + + ùúÉ ùëÜ‚àí ùúÉ ùëÅ + ùëù ùëñ‚àí + + ( 1 ‚àí ùúÉ ùëÜ + ) ( 1 ‚àí ùúÉ ùëÅ‚àí ) ùëù ùëñ + ‚àí + ùúÉ ùëÜ‚àí ( 1 ‚àí ùúÉ ùëÅ‚àí ) ùëù ùëñ‚àí‚àí , ùúã ùëñ + ‚àí = ùúÉ ùëÜ + ( 1 ‚àí ùúÉ ùëÅ + ) ùëù ùëñ + + + ( 1 ‚àí ùúÉ ùëÜ‚àí ) ( 1 ‚àí ùúÉ ùëÅ + ) ùëù ùëñ‚àí + + ùúÉ ùëÜ + ùúÉ ùëÅ‚àí ùëù ùëñ + ‚àí + ùúÉ ùëÜ‚àí ( 1 ‚àí ùúÉ ùëÅ‚àí ) ùëù ùëñ‚àí‚àí , ùúã ùëñ‚àí‚àí = ( 1 ‚àí ùúÉ ùëÜ + ) ( 1 ‚àí ùúÉ ùëÅ + ) ùëù ùëñ + + + ùúÉ ùëÜ‚àí ( 1 ‚àí ùúÉ ùëÅ + ) ùëù ùëñ‚àí + + ( 1 ‚àí ùúÉ ùëÜ + ) ùúÉ ùëÅ‚àí ùëù ùëñ + ‚àí + ùúÉ ùëÜ‚àí ùúÉ ùëÅ‚àí ùëù ùëñ‚àí‚àí . The underlying probability of antibody status accounts both for the probability of natural infection ‚ãã ùëñ and vaccination status , ùúê ùëñ ‚àà { 0 , 1 } . Following previous modeling frameworks , 1 , 2 we modeled the probability of natural infection as a function of sex and age category , accounting for household infection clustering through a random effect , ùõº ‚Ñé : ùëôùëúùëîùëñùë° ( ‚ãã ùëñ ) = ùõº ‚Ñé + ùöæ ùíä ùú∑ ùõº ‚Ñé ~ ùëÅùëúùëüùëöùëéùëô ( 0 , ùúé ‚Ñé2 ) , where ùöæ ùëñ is the matrix of covariates , and ùú∑ the vector of regression coefficients . The probabilities of antibody status are then given by : ùëù ùëñ + + = ùõæ + + ‚ãã ùëñ + ùõæ ‚àí + ùë£ ùëñ ùëù ùëñ‚àí + = ùõæ ‚àí + ‚ãã ùëñ ( 1 ‚àí ùë£ ùëñ ) ùëù ùëñ + ‚àí = ( 1 ‚àí‚ãã ùëñ ) ùë£ ùëñ + ùõæ + ‚àí ‚ãã ùëñ ùëù ùëñ‚àí‚àí = 1 ‚àí ùë£ ùëñ ( 1 ‚àí‚ãã ùëñ ) ‚àí ‚ãã ùëñ , where ùõæ + + , ùõæ ‚àí + , ùõæ + ‚àí are the conditional probability of having ùëÜ + ùëÅ + , ùëÜ ‚àí ùëÅ + , ùëÜ + ùëÅ ‚àí responses , respectively , upon natural infection , ùë£ ùëñ is the probability of having a vaccine - induced ùëÜ + response as a function of the conditional probability of antibody response upon infection ùúÇ ùëñ , ùë£ ùëñ = ùúÇ ùëñ √ó ùúê ùëñ . 4 S2 . 1 . 2 Vaccination To obtain population - level seroprevalence estimates , we also modeled the proportion of vaccinated individuals in each sex / age class following the approach used for natural infection : ùúê ùëñ ~ Bernoulli ( ùúô ùëñ ) , ùëôùëúùëîùëñùë° ( ùúô ùëñ ) = ùõº ùúê , ‚Ñé + ùöæ ùëñ ùú∑ ùùä , ùõº ùúê , ‚Ñé ~ Normal ( 0 , ùúé ùúê2 ) . S2 . 1 . 3 Diagnostic test performance The individual performance of both N and S tests was incorporated hierarchically following Gelman & Carpenter . 4 The sensitivity , ùúÉ + , was determined using ùëõ + RT - PCR positive controls from a laboratory validation study , 7 of which ùë• + tested positive . The specificity , ùúÉ ‚àí , was determined using ùëõ ‚àí pre - pandemic negative controls , of which ùë• ‚àí tested positive . For the Roche N test , these values were modulated by data in Ainsworth et al . 8 For the Roche S test , the laboratory study data were modulated by those available on the Roche website ( last accessed July 20 , 2022 : https : / / diagnostics . roche . com / global / en / products / params / elecsys - anti - sars - cov - 2 - s . html ) . S2 . 1 . 4 Priors We followed a similar setting of the priors on the tests‚Äô sensitivity and specificity as Gelman & Carpenter ( 7 ) . For study j , the specificity ùúÉ ùëó‚àí and sensitivity ùúÉ ùëó + were drawn from normal distributions on the log odds scale : ùëôùëúùëîùëñùë° ( ùúÉ ùëó ‚àí ) ~ Normal ( ùúá ùúÉ‚àí , ùúé ùúÉ‚àí ) ùëôùëúùëîùëñùë° ( ùúÉ ùëó + ) ~ Normal ( ùúá ùúÉ + , ùúé ùúÉ + ) . Hyperparameters ùúá ùëß and ùúé ùëß for ùëß ‚àà { ùúÉ ‚àí , ùúÉ + } follow , on the logit scale , normal distributions ùúá ùëß ~ ùí© ( 4 , 2 ) and positive half - normals ùúé ùëß ~ ùí© + ( 0 , 1 ) , respectively . These priors on test performance were identical for both the Roche S and Roche N tests . We used standard normal ùí© ( 0 , 1 ) priors for the logistic regression coefficients for infection ùú∑ . For coefficients of vaccination ùú∑ ùùä we used ùí© ( 0 , 5 ) . The priors for the means of the household random effects ùõº ‚Ñé and ùõº ‚Ñé , ùúê , followed standard normal , and for standard deviations of the household random effects were positive half - normals , ùúé ‚Ñé ~ ùí© + ( 0 , 2 ) and ùúé ùúê ~ ùí© + ( 0 , 2 ) . We used a Dirichlet prior on the conditional probability of having ùëÜ + ùëÅ + , ùëÜ ‚àí ùëÅ + , ùëÜ + ùëÅ ‚àí responses upon natural infection , ùõæ + + , ùõæ ‚àí + , ùõæ + ‚àí , ùõæ ~ Dir ( 10 , 1 , 1 ) , to highly favour production of both anti - S and anti - N antibodies upon infection . Finally , we put a strong prior on the conditional probability of antibody response after vaccination ùúÇ ùëñ ~ Beta ( 10 , 0 . 1 ) . S2 . 1 . 5 Implementation The model was coded in the probabilistic programming language Stan 9 using the Rstan package . 10 R version 4 . 1 11 was used for data analysis . Four chains were run with 1500 iterations each , 250 of which were warmup , to give a total of 5000 posterior samples . Convergence was assessed by checking that R ÃÇ ‚âà 1 , that the effective sample size was reasonable for all parameters , and visually using shinystan 12 diagnostics checks . S2 . 2 Neutralization capacity modeling The two main aims of the analysis were first to assess the impact of age , sex , and vaccination and infection status on the variant - specific neutralization capacity , and second to produce population - level estimates through post - stratification . S2 . 2 . 1 Model description We developed a logistic regression model accounting for participant characteristics as well as neutralization test performance . The serum sample of participant ùëñ was considered to have neutralization capacity if its ED50 % value was above 50 . 13 We modeled the presence of neutralization ( ùëù ùëñ ‚àà { 0 , 1 } ) as a function of the participant‚Äôs characteristics as : ùë¶ ùëñ ‚àº ùêµùëíùëüùëõùëúùë¢ùëôùëôùëñ ( ùúÉ + ùëù ùëñ + ( 1 ‚àí ùúÉ ‚àí ) ( 1 ‚àí ùëù ùëñ ) ) logit ( ùëù ùëñ ) = ùõº + ùõΩ 1 sex ùëñ + ùõΩ 2 age ùëñ + ùõΩ 3 latest _ inf ùëñ + ùõΩ 4 vacc _ status ùëñ ùëõ ùë°ùëù ‚àº ùêµùëñùëõùëúùëöùëñùëéùëô ( ùëÅ + , ùúÉ + ) 5 ùëõ ùëìùëù ‚àº ùêµùëñùëõùëúùëöùëñùëéùëô ( ùëÅ ‚àí , ùúÉ ‚àí ) where ùúÉ + and ùúÉ ‚àí are the pseudo - neutralization test‚Äôs sensitivity and specificity which are informed by the number of true ( ùëõ ùë°ùëù = 118 ) and false positives ( ùëõ ùëìùëù = 0 ) among the validation set of positive ( ùëÅ + = 122 ) and negative ( ùëÅ ‚àí = 84 ) controls in Fenwick et al . 13 Latest infection status indicates whether participants were infected by a pre - Omicron SARS - CoV - 2 variant ( infection prior to January 2022 as Omicron became dominant in late December 2021 in Geneva , Figure S6 ) , an Omicron variant ( infection in 2022 ) , or uninfected at the time of blood draw . Infection status was assessed based on anti - N and anti - S Roche serology , and latest infection date was based on self - reported dates of positive tests ( RT - PCR or rapid antigenic test , including self - test ) . Among participants with known infection ( positive anti - N or positive anti - S in the absence of vaccination ) , 41 % ( 341 / 837 ) did not report any positive tests . The unknown infection date ( before January 2022 or during 2022 ) for these participants was marginalized out within the modeling framework using prior probabilities of infection before or after January 2022 ( non - Omicron vs . Omicron infections ) . Prior probabilities were determined based on the difference between the age - specific cumulative infection probabilities in this work with those of our previous estimates in June - July 2021 ( Figure S6 ) . 3 These differences in cumulative attack rates account both for the Delta - driven and Omicron - driven waves in Geneva ( Figure S6 ) . To compute the prior probabilities of non - Omicron vs . Omicron infections we therefore assumed that approximately 80 % of the cumulative attack rate between the two serosurveys was due to Omicron variants based on the ratio of reported cases in the Delta vs . Omicron periods ( 31953 cases were reported between July 15 th and December 25 th , 2021 when the Delta variant were dominant , and 123554 cases between December 26 th , 2021 and when the serosurvey started on April 29 th , 2022 when Omicron subvariants were dominant ) . Parameter priors were set following the approach for modeling antibody presence described in section S2 . 1 . 4 using ùëÅùëúùëüùëöùëéùëô ( 0 , 1 ) priors on the intercept and regression parameters . S2 . 2 . 2 Alternative models To account for possible effect modification of vaccination effect by infection status , we also fit a model with interaction terms between vaccination status and latest infection status . Over - dispersion of neutralization capacity conditional on participant characteristics was tested through a participant - level additive random effect on the logit - scale . Finally we also tested whether there was support for differential pseudo - neutralization test performance for children ( < 12 years old ) and other participants given that the test in Fenwick et al . 13 was validated on adult samples only . This was done following a hierarchical model on test performance as done for accounting for multiple validation sets to infer antibody presence in this work and elsewhere . 3 S2 . 2 . 3 Model selection Model selection was performed through Bayesian estimates of leave - one - out cross - validation error , 14 as implemented in the loo R package . 15 We accounted for model comparison uncertainty by retaining the simplest model among the set of models with an estimated pairwise log - predictive density difference larger than 2 standard errors . Across all variants , this model selection procedure retained the additive logistic model without over - dispersion and same test performance for children and other participants . S2 . 2 . 4 Post - stratification Following the methods described for antibody presence , we obtained population - level estimates of neutralization capacity through post - stratification based on variant - specific parameters estimates from the additive logistic models . For vaccination we used the official cantonal statistics on vaccination as done for antibody presence ( Table S2 ) . For latest infection status we used our estimates of cumulative attack rates based on anti - N positive serology as described in section S . 2 . 1 ( Figure S6 ) . Stratification across combinations of latest infection status and vaccination status were based on observed age - specific frequencies in our full analytical sample , scaled to match cantonal vaccination data and our inferred total infection prevalence . Link to GitHub repository containing all code to reproduce the analysis as well as code for the creation of a synthetic dataset on which to run the analysis code : https : / / github . com / UEP - HUG / sp4 _ public Link to script to process neutralizing antibody data from the Luminex instrument : https : / / zenodo . org / record / 7124818 6 Figure S1 . Timeline of serosurveys and vaccination rollout in Geneva , Switzerland a By the time of the third serosurvey ( June ‚Äì July 2021 ) , the two vaccines approved for use in Switzerland were Comirnaty ( BNT162b2 , mRNA BioNTech - Pfizer , Mainz , Germany / New York City , United States ) and Spikevax ( mRNA - 1273 , Moderna , Cambridge , US ) ; by the fourth serosurvey , the Janssen COVID - 19 vaccine ( Ad26 . COV - S recombinant , Janssen - Cilag International , Bersee , Belgium ) was also approved . Eligibility for vaccination allowed individuals to register for an appointment to receive the first vaccine dose . 7 Figure S2 . Participants recruitment and inclusion into analytical samples 8005 index individuals invited to participate 7030 invited index new individuals ( OCPM ) 975 invited index returning individuals ( previous serosurveys ) - 252 letters returned - 3 deceased - 22 ineligible ( 17 moved away from Geneva , 5 not speaking French ) - 237 not available ( 136 not in Geneva during study , 86 hospitalized or health - related commuting difficulty , 15 did not find a suitable appointment time ) - 878 refusals - 4449 did not answer - 16 letters returned - 1 deceased - 14 ineligible ( 14 moved away from Geneva ) - 43 not available ( 28 not in Geneva during study , 13 hospitalized or health - related commuting difficulty , 2 did not find a suitable appointment time ) - 66 refusals - 262 did not answer 1189 index participants + 788 household member participants 573 index participants 2521 participants included in global seroprevalence analysis 1160 index participants included in neutralizing antibodies analysis 1881 participants included in seroprevalence analysis with additional post - stratification by education Due to missing data : * 17 index participants excluded from all analyses + 12 index participants excluded from neutralizing antibodies analysis * 12 household member participants excluded from global seroprevalence analysis 640 participants excluded ( only ) from seroprevalence analysis with additional post - stratification by education : * 541 aged < 18 years * 99 missing education data 8 Figure S3 . Reasons for refusal to participate to the study as provided by invited individuals Excluding those ineligible and not available , 17 % of the remaining invited individuals ( 944 / 5655 ) provided us with one or more reasons for their refusal to participate to the study ( either by direct contact by phone or email or by completing the pseudo - anonymized reply form provided with the reminder letter / email ) . On the same form , invited individuals were asked , if willing , to indicate their COVID - 19 vaccination status and education level ( as highest level diploma obtained ) . The study sample had a higher proportion of individuals with tertiary education as well as a higher proportion of vaccinated individuals than this ‚Äúrefusing‚Äù sample ; in line with what we observed when comparing the study sample with the official numbers from the canton of Geneva . Ages ‚Äú18 + ‚Äù or ‚Äú0 - 17‚Äù refer to age of invited index individual , in years . 9 Figure S4 . Comparison of age and sex composition of study samples ( bars ) and the Geneva population ( dots ) Dark yellow represents men ; blue represents women . A . Total sample N = 2521 used in estimations of seroprevalence of antibodies of vaccination and / or infection and infection - only origin ; B . Subsample N = 1160 used in estimation of seroprevalence of neutralizing antibodies . A . Main sample vs Geneva population B . Subsample vs Geneva population 10 Figure S5 . Antibodies‚Äô response category and vaccination status Number of participants in the four possible categories of the anti - S and anti - N serological tests . + indicates antibodies detected above positivity threshold ; - indicates no antibodies detected above positivity threshold . Data on vaccination status was self - reported by the participants at the moment of the blood drawing . 11 Figure S6 . Confirmed SARS - CoV - 2 infection cases and estimated seroprevalence of anti - SARS - CoV - 2 antibodies in the general population of Geneva , Switzerland , April 2020 to June 2022 A . Confirmed SARS - CoV - 2 cases in the general population of Geneva . Cantonal data presented in grey ( available from : https : / / infocovid . smc . unige . ch ) and serosurvey timings ( colour shaded ) . Proportion of SARS - CoV - 2 variants was estimated through multinomial spline regression of publicly available weekly sequence data from the Covariants project ( https : / / github . com / hodcroftlab / covariants / ) , following analysis from https : / / www . hug . ch / laboratoire - virologie / surveillance - variants - sars - cov - 2 - geneve - national ( report May 2022 ) . B . Seroprevalence estimates by age group , serosurvey period and origin of antibody response . Symbols indicate the antibody origin : dot indicates antibodies developed after infection ( during the first two serosurveys , which took place before vaccination became available , infection was the only possible antibody origin ) . For first serosurvey the 0 - 5 group only included children aged 5 years ( 5 ) ; triangle indicates antibodies developed after infection and / or vaccination . Vertical bars represent 95 % credible intervals in seroprevalence estimations . 12 Figure S7 . Distribution of ED50 % values for all tested SARS - CoV - 2 variants by age group ED50 % : mean serum dilution needed to achieve 50 % neutralization . The cell - free surrogate neutralization assay can be multiplexed to test up to ten variants on the same sample . For logistics reasons , numbers of tested samples per variant were as follows : N = 1160 for D614G , Alpha , Beta , Gamma , Delta , Lambda , Omicron BA . 1 , and Omicron BA . 2 ; N = 1078 for Omicron BA . 4 / BA . 5 ; N = 995 for Omicron BA . 2 . 12 . 1 ; N = 165 for Kappa ; and N = 82 for Iota . Black horizontal bars in each violin indicate quartiles . Age group 13 Figure S8 . Seroprevalence of neutralizing antibodies against main SARS - CoV - 2 variants in the general population of Geneva , Switzerland , April 29 th to June 9 th , 2022 Panels show the effect of covariates tested in the model : sex , age , and infection and vaccination statuses ( self - reported ) . Global seroprevalence estimates for anti - S and anti - N antibodies are included in black in the three left panels for comparison purposes . Symbols indicate the antibody origin : dot indicates antibodies developed after infection ( anti - N ) ; triangle indicates antibodies developed after infection and / or vaccination ( anti - S ) ; and square indicates neutralizing antibodies ( cell - free surrogate neutralization assay ) . Vertical bars represent 95 % credible intervals . 14 Figure S9 . Marginal posterior distributions of ( A ) the probability of any antibody by age group with and without post - stratification to the vaccination levels in the population of Geneva , and ( B ) the probability of infection by age group and sex A B Black vertical lines indicate quartiles . 15 Figure S10 . Marginal posterior distributions for Roche - N and Roche - S sensitivity and specificity Black vertical lines indicate quartiles . 16 Figure S11 . Marginal posterior distributions of regression coefficients for probability of antibody presence of infection origin and for probability of vaccination The intercept term includes the reference categories for sex ( Female ) and age ( 25 - 34 ) . Black vertical lines indicate quartiles . 17 Figure S12 . Neutralization assay results for each ( sub ) variant versus Roche anti - S values ED50 % : mean serum dilution needed to achieve 50 % neutralization . Roche anti - S values are expressed in WHO international units ( obtained after multiplying Roche anti - S values by a conversion factor of 1 . 184 ) . Dashed black lines indicate thresholds for positivity . 18 Figure S13 . Neutralization assay results for each ( sub ) variant versus Roche anti - S values , stratified by vaccination and infection status ED50 % : mean serum dilution needed to achieve 50 % neutralization . Roche anti - S values are expressed in WHO international units ( obtained after multiplying Roche anti - S values by a conversion factor of 1 . 184 ) . Dashed black lines indicate thresholds for positivity . 19 Table S1 . Comparison of education level in the main study sample and in Geneva population Education level Study sample N ( % ) Geneva population N ( % ) Primary 213 ( 11 . 3 ) 98246 ( 26 . 6 ) Secondary 597 ( 31 . 7 ) 118125 ( 32 . 0 ) Tertiary 1071 ( 56 . 9 ) 153334 ( 41 . 5 ) Primary education corresponds to mandatory schooling ; secondary education includes high - school diploma or apprenticeship training ; tertiary education includes university - level diploma . Geneva population data available from : https : / / www . ge . ch / statistique / domaines / 15 / 15 _ 03 / tableaux . asp # 1 20 Table S2 . Comparison of proportion vaccinated in main study sample and in Geneva population Study sample Geneva population N Vaccinated ( self - reported ) N ( % ) N Vaccinated N ( % ) Total 2521 1902 ( 75 . 4 ) 506343 360010 ( 71 . 1 ) Men 1129 844 ( 74 . 8 ) 245320 174423 ( 69 . 6 ) Women 1392 1058 ( 76 . 0 ) 261023 185587 ( 72 . 5 ) Age , y 0 - 9 304 18 ( 5 . 9 ) 53083 1152 ( 2 . 2 ) 10 - 19 280 150 ( 53 . 6 ) 53405 27803 ( 52 . 1 ) 20 - 29 219 198 ( 90 . 4 ) 64680 47779 ( 73 . 9 ) 30 - 39 399 360 ( 90 . 2 ) 76299 58788 ( 77 . 1 ) 40 - 49 547 485 ( 88 . 7 ) 76578 62985 ( 82 . 3 ) 50 - 59 278 242 ( 87 . 1 ) 72233 61347 ( 84 . 9 ) 60 - 69 212 190 ( 89 . 6 ) 47544 42181 ( 88 . 7 ) 70 - 79 181 175 ( 96 . 7 ) 36849 33054 ( 89 . 7 ) ‚â•80 71 64 ( 90 . 1 ) 25672 24848 ( 96 . 8 ) Data on individuals vaccinated with at least 1 dose in study sample to match data on individuals vaccinated in the general population of Geneva with at least 1 dose up to May 8 th , 2022 . Geneva population data available from : https : / / www . covid19 . admin . ch / en / vaccination / persons / d / demography ? geo = GE & demoSum = total & demoAge = mi nOne 21 Table S3 . Prevalence ratio for seroprevalence of anti - SARS - CoV - 2 antibodies in Geneva , Switzerland , April 29 th to June 9 th , 2022 Antibodies of any origin Antibodies of infection origin Participants n ( % ) Prevalence ratio ( 95 % CrI ) a P value Prevalence ratio ( 95 % CrI ) a P value M o d e l 1 Men 1129 ( 44 . 8 ) 0 . 99 ( 0 . 98 - 1 . 00 ) 0 . 13 0 . 97 ( 0 . 93 - 1 . 01 ) 0 . 13 Women 1392 ( 55 . 2 ) 1 . 00 ( ref . ) 1 . 00 ( ref . ) Age , y 0 - 5 144 ( 5 . 7 ) 0 . 83 ( 0 . 75 - 0 . 89 ) < 0 . 001 0 . 97 ( 0 . 88 - 1 . 07 ) 0 . 57 6 - 11 242 ( 9 . 6 ) 0 . 96 ( 0 . 92 - 1 . 00 ) 0 . 03 1 . 14 ( 1 . 07 - 1 . 21 ) < 0 . 0001 12 - 17 155 ( 6 . 2 ) 0 . 99 ( 0 . 95 - 1 . 01 ) 0 . 36 1 . 09 ( 1 . 00 - 1 . 18 ) 0 . 04 18 - 24 169 ( 6 . 7 ) 1 . 00 ( 0 . 98 - 1 . 02 ) 0 . 90 1 . 06 ( 0 . 98 - 1 . 15 ) 0 . 17 25 - 34 267 ( 10 . 6 ) 1 . 00 ( ref . ) 1 . 00 ( ref . ) 35 - 49 787 ( 31 . 2 ) 1 . 00 ( 0 . 99 - 1 . 01 ) 0 . 86 0 . 95 ( 0 . 88 - 1 . 01 ) 0 . 10 50 - 64 400 ( 15 . 9 ) 1 . 01 ( 0 . 99 - 1 . 02 ) 0 . 44 0 . 86 ( 0 . 79 - 0 . 94 ) < 0 . 001 65 - 74 183 ( 7 . 3 ) 1 . 00 ( 0 . 99 - 1 . 02 ) 0 . 87 0 . 71 ( 0 . 61 - 0 . 80 ) < 0 . 0001 ‚â•75 174 ( 6 . 9 ) 1 . 02 ( 1 . 01 - 1 . 03 ) < 0 . 01 0 . 59 ( 0 . 49 - 0 . 69 ) < 0 . 0001 M o d e l 2 Men 806 ( 42 . 8 ) 0 . 99 ( 0 . 98 - 1 . 00 ) 0 . 23 0 . 97 ( 0 . 92 - 1 . 02 ) 0 . 23 Women 1075 ( 57 . 2 ) 1 . 00 ( ref . ) 1 . 00 ( ref . ) Age , y 18 - 24 160 ( 8 . 5 ) 1 . 00 ( 0 . 97 - 1 . 02 ) 0 . 97 1 . 08 ( 0 . 98 - 1 . 17 ) 0 . 13 25 - 44 708 ( 37 . 6 ) 1 . 00 ( ref . ) 1 . 00 ( ref . ) 45 - 64 670 ( 35 . 6 ) 1 . 00 ( 0 . 99 - 1 . 01 ) 0 . 48 0 . 90 ( 0 . 84 - 0 . 97 ) 0 . 005 ‚â•65 343 ( 18 . 2 ) 1 . 01 ( 1 . 00 - 1 . 02 ) 0 . 12 0 . 65 ( 0 . 56 - 0 . 73 ) < 0 . 0001 Education level b Primary 213 ( 11 . 3 ) 1 . 01 ( 0 . 99 - 1 . 02 ) 0 . 23 1 . 05 ( 0 . 97 - 1 . 13 ) 0 . 28 Secondary 597 ( 31 . 7 ) 1 . 01 ( 1 . 00 - 1 . 02 ) 0 . 21 1 . 04 ( 0 . 98 - 1 . 09 ) 0 . 24 Tertiary 1071 ( 56 . 9 ) 1 . 00 ( ref . ) 1 . 00 ( ref . ) CrI : credible interval a Prevalence ratio ( 95 % credible interval ) from Bayesian multinomial regression models . Model 1 estimates ( N = 2521 , participants of all ages ) accounted for sex , age , test performance , and household clustering , with the reference group being women aged 25 - 34 years . Model 2 estimates ( N = 1881 , participants aged ‚â•18 years only ) accounted for sex , age , education level , test performance , and household clustering , with the reference group being women aged 25 - 44 years with tertiary education level . b Self - reported education level among participants aged ‚â•18 years . Primary education corresponds to mandatory schooling ; secondary education includes high - school diploma or apprenticeship training ; tertiary education includes university - level diploma . 22 Table S4 . Educational level of sample , serological results , and seroprevalence estimates in Geneva , Switzerland , April 29 th to June 9 th , 2022 Seropositive b Seroprevalence c Participants Vaccinated ( self - reported ) a Anti - SARS - CoV - 2 S protein Anti - SARS - CoV - 2 N protein Antibodies of any origin Antibodies of infection origin n ( % ) n ( % ) n ( % ) n ( % ) % ( 95 % CrI ) % ( 95 % CrI ) Total 1881 1699 ( 90 . 3 ) 1849 ( 98 . 3 ) 1239 ( 65 . 9 ) 95 . 6 ( 95 . 0 - 96 . 2 ) 71 . 8 ( 68 . 5 - 75 . 1 ) Men 806 ( 42 . 8 ) 737 ( 91 . 4 ) 791 ( 98 . 1 ) 514 ( 63 . 8 ) 95 . 3 ( 94 . 6 - 96 . 1 ) 70 . 9 ( 66 . 8 - 75 . 1 ) Women 1075 ( 57 . 2 ) 962 ( 89 . 5 ) 1058 ( 98 . 4 ) 725 ( 67 . 4 ) 95 . 8 ( 95 . 2 - 96 . 5 ) 72 . 6 ( 68 . 8 - 76 . 4 ) Age , y 18 - 24 160 ( 8 . 5 ) 143 ( 89 . 4 ) 160 ( 100 . 0 ) 126 ( 78 . 8 ) 95 . 5 ( 93 . 3 - 97 . 5 ) 85 . 7 ( 78 . 6 - 92 . 2 ) 25 - 44 708 ( 37 . 6 ) 645 ( 91 . 1 ) 699 ( 98 . 7 ) 519 ( 73 . 3 ) 95 . 2 ( 94 . 3 - 96 . 2 ) 78 . 7 ( 74 . 6 - 82 . 8 ) 45 - 64 670 ( 35 . 6 ) 585 ( 87 . 3 ) 656 ( 97 . 9 ) 435 ( 64 . 9 ) 95 . 7 ( 94 . 9 - 96 . 4 ) 71 . 6 ( 66 . 8 - 76 . 2 ) ‚â•65 343 ( 18 . 2 ) 326 ( 95 . 0 ) 334 ( 97 . 4 ) 159 ( 46 . 4 ) 96 . 1 ( 95 . 6 - 96 . 6 ) 52 . 6 ( 46 . 5 - 58 . 8 ) Education level d Primary 213 ( 11 . 3 ) 192 ( 90 . 1 ) 209 ( 98 . 1 ) 142 ( 66 . 7 ) 96 . 0 ( 94 . 8 - 97 . 1 ) 73 . 1 ( 66 . 2 - 80 . 0 ) Secondary 597 ( 31 . 7 ) 508 ( 85 . 1 ) 578 ( 96 . 8 ) 402 ( 67 . 3 ) 95 . 8 ( 95 . 0 - 96 . 6 ) 72 . 4 ( 68 . 1 - 76 . 8 ) Tertiary 1071 ( 56 . 9 ) 999 ( 93 . 3 ) 1062 ( 99 . 2 ) 695 ( 64 . 9 ) 95 . 2 ( 94 . 5 - 95 . 9 ) 70 . 4 ( 66 . 8 - 74 . 1 ) CrI : credible interval ; N : nucleocapsid protein ; S : spike protein ; SARS - CoV - 2 : severe acute respiratory syndrome coronavirus 2 . a Self - reported having received at least 1 dose of the COVID - 19 vaccine before blood sample was drawn . b Serology based on Roche Elecsys anti - SARS - CoV - 2 S immunoassay and N immunoassay , respectively . c Seroprevalence estimates reported as % and 95 % credible interval , adjusted for test performance of both immunoassays and post - stratified to account for age , sex , and education distribution in the Geneva general population and for household clustering of infection and vaccination . Seroprevalence of any antibodies is based on proportion of participants with any anti - SARS - CoV - 2 antibodies , additionally post - stratified to the vaccination data in the general population of Geneva ; seroprevalence of infection antibodies is based on proportion of participants who were naturally infected ( but could also have been vaccinated ) . d Self - reported education level among participants aged ‚â•18 years . Primary education corresponds to mandatory schooling ; secondary education includes high - school diploma or apprenticeship training ; tertiary education includes university - level diploma . 23 Table S5 . Characteristics of main sample and subsample analyzed in this study Total seroprevalence sample Neutralizing antibodies sample n ( % ) n ( % ) Total 2521 1160 Men 1129 ( 44 . 8 ) 528 ( 45 . 6 ) Women 1392 ( 55 . 2 ) 632 ( 54 . 4 ) Age , y 0 - 5 144 ( 5 . 7 ) 91 ( 7 . 9 ) 6 - 11 242 ( 9 . 6 ) 128 ( 11 . 0 ) 12 - 17 155 ( 6 . 2 ) 109 ( 9 . 4 ) 18 - 24 169 ( 6 . 7 ) 95 ( 8 . 2 ) 25 - 34 267 ( 10 . 6 ) 128 ( 11 . 0 ) 35 - 49 787 ( 31 . 2 ) 192 ( 16 . 6 ) 50 - 64 400 ( 15 . 9 ) 193 ( 16 . 7 ) 65 - 74 183 ( 7 . 3 ) 117 ( 10 . 1 ) ‚â•75 174 ( 6 . 9 ) 107 ( 9 . 2 ) Seropositive for anti - N antibodies 1765 ( 70 . 0 ) 811 ( 70 . 0 ) 24 Table S6 . Demographic characteristics of subsample , serological results , and seroprevalence estimates in Geneva , Switzerland , April 29 th to June 9 th , 2022 Seropositive b Seroprevalence c Participants Vaccinated ( self - reported ) a Anti - SARS - CoV - 2 S protein Anti - SARS - CoV - 2 N protein Antibodies of any origin Antibodies of infection origin n ( % ) n ( % ) n ( % ) n ( % ) % ( 95 % CrI ) % ( 95 % CrI ) Total 1160 831 ( 71 . 6 ) 1119 ( 96 . 5 ) 813 ( 70 . 1 ) 94 . 4 ( 93 . 5 - 95 . 3 ) 74 . 3 ( 70 . 9 - 77 . 7 ) Men 528 ( 45 . 6 ) 372 ( 70 . 3 ) 506 ( 95 . 7 ) 359 ( 67 . 9 ) 93 . 8 ( 92 . 6 - 95 . 0 ) 72 . 8 ( 68 . 2 - 77 . 4 ) Women 632 ( 54 . 4 ) 459 ( 72 . 7 ) 613 ( 97 . 1 ) 454 ( 71 . 9 ) 95 . 0 ( 94 . 0 - 96 . 0 ) 75 . 7 ( 71 . 6 - 79 . 8 ) Age , y 0 - 5 91 ( 7 . 9 ) 3 ( 3 . 3 ) 72 ( 79 . 1 ) 67 ( 73 . 6 ) 78 . 2 ( 69 . 4 - 85 . 9 ) 77 . 7 ( 68 . 7 - 85 . 6 ) 6 - 11 128 ( 11 . 0 ) 13 ( 10 . 2 ) 124 ( 96 . 9 ) 115 ( 89 . 8 ) 94 . 5 ( 90 . 0 - 97 . 9 ) 94 . 2 ( 89 . 5 - 97 . 8 ) 12 - 17 109 ( 9 . 4 ) 69 ( 63 . 3 ) 107 ( 98 . 2 ) 90 ( 82 . 6 ) 94 . 2 ( 90 . 4 - 97 . 4 ) 88 . 2 ( 80 . 4 - 94 . 7 ) 18 - 24 95 ( 8 . 2 ) 85 ( 89 . 5 ) 95 ( 100 . 0 ) 79 ( 83 . 2 ) 96 . 6 ( 93 . 9 - 98 . 8 ) 89 . 3 ( 80 . 7 - 96 . 1 ) 25 - 34 128 ( 11 . 0 ) 118 ( 92 . 2 ) 128 ( 100 . 0 ) 103 ( 80 . 5 ) 95 . 7 ( 94 . 1 - 97 . 1 ) 82 . 6 ( 76 . 0 - 88 . 3 ) 35 - 49 192 ( 16 . 6 ) 168 ( 87 . 5 ) 191 ( 99 . 5 ) 133 ( 69 . 3 ) 95 . 2 ( 93 . 7 - 96 . 6 ) 75 . 2 ( 68 . 0 - 82 . 5 ) 50 - 64 193 ( 16 . 7 ) 165 ( 85 . 5 ) 183 ( 94 . 8 ) 121 ( 62 . 7 ) 95 . 4 ( 94 . 3 - 96 . 5 ) 67 . 7 ( 60 . 0 - 75 . 2 ) 65 - 74 117 ( 10 . 1 ) 110 ( 94 . 0 ) 115 ( 98 . 3 ) 58 ( 49 . 6 ) 95 . 1 ( 94 . 0 - 96 . 2 ) 55 . 3 ( 45 . 2 - 65 . 1 ) ‚â•75 107 ( 9 . 2 ) 100 ( 93 . 5 ) 104 ( 97 . 2 ) 47 ( 43 . 9 ) 96 . 9 ( 96 . 3 - 97 . 5 ) 49 . 7 ( 39 . 9 - 60 . 0 ) CrI : credible interval ; N : nucleocapsid protein ; S : spike protein ; SARS - CoV - 2 : severe acute respiratory syndrome coronavirus 2 . a Self - reported having received at least 1 dose of the COVID - 19 vaccine before blood sample was drawn . b Serology based on Roche Elecsys anti - SARS - CoV - 2 S immunoassay and N immunoassay , respectively . c Seroprevalence estimates reported as % and 95 % credible interval , adjusted for test performance of both immunoassays and post - stratified to account for the sex and age distribution of the Geneva general population . Seroprevalence of antibodies of any origin is based on proportion of participants with any anti - SARS - CoV - 2 antibodies , additionally post - stratified to the vaccination data in the general population of Geneva ; seroprevalence of infection antibodies is based on proportion of participants who were naturally infected ( but could have also been vaccinated ) . 25 Table S7 . Seroprevalence estimates of neutralizing anti - SARS - CoV - 2 antibodies against main variants in the general population of Geneva , Switzerland , April 29 th to June 9 th , 2022 SARS - CoV - 2 variant D614G Alpha Beta Gamma n n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) b Total 1160 910 ( 78 . 4 ) 78 . 3 ( 76 . 0 - 80 . 7 ) 918 ( 79 . 1 ) 79 . 5 ( 77 . 1 - 81 . 8 ) 704 ( 60 . 7 ) 61 . 8 ( 58 . 6 - 64 . 9 ) 871 ( 75 . 1 ) 74 . 8 ( 72 . 3 - 77 . 1 ) Men 631 506 ( 80 . 2 ) 79 . 2 ( 76 . 5 - 81 . 9 ) 510 ( 80 . 8 ) 80 . 4 ( 77 . 5 - 83 . 1 ) 395 ( 62 . 6 ) 62 . 8 ( 59 . 0 - 66 . 5 ) 485 ( 76 . 9 ) 75 . 9 ( 73 . 1 - 78 . 7 ) Women 529 404 ( 76 . 4 ) 77 . 4 ( 74 . 2 - 80 . 6 ) 408 ( 77 . 1 ) 78 . 6 ( 75 . 4 - 81 . 8 ) 309 ( 58 . 4 ) 60 . 8 ( 56 . 7 - 64 . 8 ) 386 ( 73 . 0 ) 73 . 6 ( 70 . 3 - 76 . 7 ) Age group , y 0 - 5 91 19 ( 20 . 9 ) 25 . 3 ( 16 . 0 - 35 . 5 ) 22 ( 24 . 2 ) 29 . 3 ( 18 . 9 - 40 . 4 ) 10 ( 11 . 0 ) 12 . 7 ( 5 . 3 - 21 . 4 ) 16 ( 17 . 6 ) 20 . 9 ( 12 . 4 - 30 . 8 ) 6 - 11 128 55 ( 43 . 0 ) 45 . 9 ( 36 . 4 - 55 . 5 ) 55 ( 43 . 0 ) 46 . 2 ( 36 . 7 - 56 . 0 ) 25 ( 19 . 5 ) 19 . 6 ( 11 . 7 - 28 . 2 ) 43 ( 33 . 6 ) 35 . 2 ( 26 . 3 - 44 . 8 ) 12 - 17 109 88 ( 80 . 7 ) 77 . 1 ( 69 . 1 - 84 . 6 ) 88 ( 80 . 7 ) 77 . 3 ( 68 . 8 - 84 . 9 ) 70 ( 64 . 2 ) 58 . 3 ( 49 . 4 - 67 . 3 ) 85 ( 78 . 0 ) 73 . 2 ( 65 . 2 - 81 . 1 ) 18 - 24 95 86 ( 90 . 5 ) 80 . 0 ( 71 . 6 - 88 . 7 ) 89 ( 93 . 7 ) 85 . 7 ( 76 . 6 - 93 . 3 ) 75 ( 78 . 9 ) 67 . 2 ( 57 . 9 - 77 . 1 ) 85 ( 89 . 5 ) 79 . 5 ( 70 . 6 - 88 . 2 ) 25 - 34 128 116 ( 90 . 6 ) 79 . 2 ( 72 . 4 - 85 . 8 ) 117 ( 91 . 4 ) 80 . 7 ( 73 . 8 - 87 . 6 ) 103 ( 80 . 5 ) 70 . 3 ( 62 . 9 - 77 . 7 ) 112 ( 87 . 5 ) 74 . 3 ( 67 . 7 - 80 . 8 ) 35 - 49 192 176 ( 91 . 7 ) 85 . 0 ( 81 . 5 - 88 . 3 ) 175 ( 91 . 1 ) 85 . 4 ( 81 . 9 - 88 . 8 ) 134 ( 69 . 8 ) 67 . 2 ( 62 . 0 - 72 . 5 ) 169 ( 88 . 0 ) 81 . 6 ( 77 . 8 - 85 . 1 ) 50 - 64 193 165 ( 85 . 5 ) 86 . 6 ( 82 . 8 - 90 . 0 ) 165 ( 85 . 5 ) 86 . 6 ( 82 . 9 - 90 . 0 ) 131 ( 67 . 9 ) 70 . 5 ( 64 . 5 - 76 . 1 ) 159 ( 82 . 4 ) 83 . 4 ( 79 . 2 - 87 . 0 ) 65 - 74 117 106 ( 90 . 6 ) 88 . 3 ( 83 . 5 - 92 . 7 ) 107 ( 91 . 5 ) 89 . 1 ( 84 . 5 - 93 . 3 ) 79 ( 67 . 5 ) 66 . 0 ( 58 . 7 - 73 . 3 ) 105 ( 89 . 7 ) 87 . 0 ( 81 . 9 - 91 . 6 ) ‚â•75 107 99 ( 92 . 5 ) 93 . 0 ( 89 . 9 - 95 . 5 ) 100 ( 93 . 5 ) 93 . 6 ( 90 . 5 - 96 . 0 ) 77 ( 72 . 0 ) 74 . 4 ( 66 . 6 - 81 . 4 ) 97 ( 90 . 7 ) 91 . 4 ( 87 . 7 - 94 . 3 ) Vaccination and infection status c Unvaccinated and uninfected 39 0 ( 0 . 0 ) 9 . 3 ( 4 . 4 - 16 . 1 ) 0 ( 0 . 0 ) 10 . 9 ( 5 . 4 - 18 . 5 ) 0 ( 0 . 0 ) 2 . 1 ( 0 . 9 - 3 . 8 ) 0 ( 0 . 0 ) 6 . 0 ( 2 . 8 - 10 . 6 ) Unvaccinated and pre - 2022 infection 55 29 ( 52 . 7 ) 43 . 5 ( 31 . 7 - 55 . 3 ) 30 ( 54 . 5 ) 47 . 4 ( 35 . 6 - 59 . 4 ) 16 ( 29 . 1 ) 16 . 1 ( 8 . 5 - 24 . 8 ) 22 ( 40 . 0 ) 32 . 1 ( 22 . 3 - 43 . 0 ) Unvaccinated and 2022 infection 94 27 ( 28 . 7 ) 38 . 5 ( 30 . 8 - 46 . 7 ) 29 ( 30 . 9 ) 42 . 5 ( 34 . 4 - 50 . 7 ) 16 ( 17 . 0 ) 26 . 5 ( 19 . 1 - 34 . 0 ) 23 ( 24 . 5 ) 31 . 9 ( 24 . 9 - 39 . 7 ) Vaccinated , no booster , and uninfected 54 38 ( 70 . 4 ) 80 . 8 ( 72 . 3 - 88 . 4 ) 38 ( 70 . 4 ) 81 . 1 ( 72 . 6 - 88 . 5 ) 11 ( 20 . 4 ) 38 . 2 ( 27 . 7 - 48 . 6 ) 34 ( 63 . 0 ) 73 . 9 ( 63 . 8 - 82 . 8 ) Vaccinated , no booster , and pre - 2022 infection 77 76 ( 98 . 7 ) 95 . 6 ( 92 . 5 - 97 . 8 ) 76 ( 98 . 7 ) 95 . 7 ( 92 . 7 - 97 . 8 ) 60 ( 77 . 9 ) 78 . 9 ( 70 . 1 - 86 . 5 ) 73 ( 94 . 8 ) 92 . 8 ( 88 . 2 - 96 . 2 ) Vaccinated , no booster , and 2022 infection 93 93 ( 100 . 0 ) 95 . 2 ( 91 . 6 - 97 . 7 ) 93 ( 100 . 0 ) 95 . 3 ( 91 . 9 - 97 . 7 ) 86 ( 92 . 5 ) 89 . 1 ( 84 . 1 - 93 . 4 ) 91 ( 97 . 8 ) 93 . 4 ( 89 . 1 - 96 . 7 ) Vaccinated , booster , and uninfected 224 221 ( 98 . 7 ) 98 . 4 ( 96 . 7 - 99 . 4 ) 222 ( 99 . 1 ) 98 . 6 ( 97 . 1 - 99 . 5 ) 140 ( 62 . 5 ) 68 . 9 ( 62 . 7 - 74 . 8 ) 216 ( 96 . 4 ) 97 . 4 ( 95 . 1 - 99 . 0 ) Vaccinated , booster , and pre - 2022 infection 73 73 ( 100 . 0 ) 99 . 7 ( 99 . 3 - 99 . 9 ) 73 ( 100 . 0 ) 99 . 7 ( 99 . 4 - 99 . 9 ) 62 ( 84 . 9 ) 93 . 8 ( 89 . 6 - 97 . 0 ) 72 ( 98 . 6 ) 99 . 5 ( 98 . 8 - 99 . 8 ) Vaccinated , booster , and 2022 infection 104 103 ( 99 . 0 ) 99 . 7 ( 99 . 2 - 99 . 9 ) 103 ( 99 . 0 ) 99 . 7 ( 99 . 3 - 99 . 9 ) 101 ( 97 . 1 ) 97 . 0 ( 94 . 9 - 98 . 4 ) 103 ( 99 . 0 ) 99 . 5 ( 98 . 9 - 99 . 9 ) a Number and proportion ( % ) above the threshold for neutralizing activity against specific variant . b Estimated seroprevalence % ( 95 % credible interval ) of neutralizing antibodies against specific variant , from regression model accounting for age , sex , self - reported most recent SARS - CoV - 2 infection and vaccination status , and post - stratifying to the demographic and vaccination and infection statuses of the Geneva general population . c Self - reported vaccination and most recent infection via a COVID - 19 diagnostic positive test ( RT - PCR or rapid antigen test , including self - test ) . The cell - free surrogate neutralization assay can be multiplexed to test up to ten variants on the same sample . For logistics reasons , numbers of tested samples per variant were as follows : N = 1160 for D614G , Alpha , Beta , Gamma , Delta , Lambda , Omicron BA . 1 , and Omicron BA . 2 ; N = 1078 for Omicron BA . 4 / BA . 5 ; N = 995 for Omicron BA . 2 . 12 . 1 ; N = 165 for Kappa ; and N = 82 for Iota . 26 Table S7 continued . Seroprevalence estimates of neutralizing anti - SARS - CoV - 2 antibodies against main variants in the general population of Geneva , Switzerland , April 29 th to June 9 th , 2022 SARS - CoV - 2 variant Delta Iota Kappa Lambda n n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) d n ( % ) a Seroprevalence % ( 95 % CrI ) d n ( % ) a Seroprevalence % ( 95 % CrI ) b Total 1160 862 ( 74 . 3 ) 75 . 7 ( 73 . 2 - 78 . 3 ) 78 ( 95 . 1 ) - 140 ( 84 . 8 ) - 893 ( 77 . 0 ) 76 . 9 ( 74 . 6 - 79 . 2 ) Men 477 ( 75 . 6 ) 76 . 4 ( 73 . 2 - 79 . 5 ) 43 ( 95 . 6 ) - 81 ( 85 . 3 ) - 499 ( 79 . 1 ) 78 . 3 ( 75 . 5 - 81 . 1 ) Women 385 ( 72 . 8 ) 75 . 1 ( 71 . 5 - 78 . 6 ) 35 ( 94 . 6 ) - 59 ( 84 . 3 ) - 394 ( 74 . 5 ) 75 . 4 ( 72 . 1 - 78 . 6 ) Age group , y 0 - 5 91 18 ( 19 . 8 ) 25 . 5 ( 15 . 6 - 36 . 0 ) - - - - 17 ( 18 . 7 ) 23 . 0 ( 14 . 1 - 33 . 6 ) 6 - 11 128 49 ( 38 . 3 ) 43 . 3 ( 33 . 6 - 53 . 1 ) - - - - 52 ( 40 . 6 ) 43 . 9 ( 34 . 6 - 53 . 3 ) 12 - 17 109 85 ( 78 . 0 ) 76 . 3 ( 67 . 6 - 84 . 4 ) - - - - 86 ( 78 . 9 ) 75 . 0 ( 66 . 7 - 82 . 8 ) 18 - 24 95 85 ( 89 . 5 ) 82 . 0 ( 72 . 3 - 90 . 5 ) 5 ( 100 . 0 ) - 9 ( 100 . 0 ) - 86 ( 90 . 5 ) 81 . 0 ( 72 . 3 - 89 . 3 ) 25 - 34 128 112 ( 87 . 5 ) 77 . 5 ( 70 . 1 - 85 . 0 ) 14 ( 93 . 3 ) - 20 ( 80 . 0 ) - 115 ( 89 . 8 ) 77 . 8 ( 70 . 8 - 84 . 7 ) 35 - 49 192 165 ( 85 . 9 ) 81 . 4 ( 77 . 0 - 85 . 4 ) 15 ( 93 . 8 ) - 29 ( 85 . 3 ) - 173 ( 90 . 1 ) 83 . 4 ( 79 . 7 - 86 . 8 ) 50 - 64 193 156 ( 80 . 8 ) 83 . 1 ( 78 . 7 - 87 . 1 ) 16 ( 94 . 1 ) - 32 ( 76 . 2 ) - 163 ( 84 . 5 ) 85 . 3 ( 81 . 6 - 88 . 6 ) 65 - 74 117 100 ( 85 . 5 ) 83 . 7 ( 77 . 9 - 89 . 1 ) 18 ( 100 . 0 ) - 29 ( 96 . 7 ) - 105 ( 89 . 7 ) 87 . 1 ( 82 . 0 - 91 . 6 ) ‚â•75 107 92 ( 86 . 0 ) 88 . 1 ( 82 . 6 - 92 . 5 ) 10 ( 90 . 9 ) - 21 ( 84 . 0 ) - 96 ( 89 . 7 ) 90 . 8 ( 86 . 5 - 93 . 9 ) Vaccination and infection status c Unvaccinated and uninfected 39 0 ( 0 . 0 ) 5 . 6 ( 2 . 7 - 9 . 7 ) 0 ( 0 . 0 ) - 0 ( 0 . 0 ) - 0 ( 0 . 0 ) 8 . 2 ( 4 . 2 - 13 . 8 ) Unvaccinated and pre - 2022 infection 55 29 ( 52 . 7 ) 45 . 3 ( 34 . 0 - 57 . 8 ) - - 0 ( 0 . 0 ) - 29 ( 52 . 7 ) 42 . 4 ( 31 . 2 - 54 . 1 ) Unvaccinated and 2022 infection 94 30 ( 31 . 9 ) 41 . 2 ( 33 . 4 - 49 . 4 ) 3 ( 100 . 0 ) - 1 ( 25 . 0 ) - 25 ( 26 . 6 ) 35 . 3 ( 27 . 6 - 43 . 0 ) Vaccinated , no booster , and uninfected 54 22 ( 40 . 7 ) 59 . 5 ( 48 . 4 - 70 . 0 ) 1 ( 50 . 0 ) - 2 ( 28 . 6 ) - 35 ( 64 . 8 ) 76 . 7 ( 67 . 9 - 84 . 7 ) Vaccinated , no booster , and pre - 2022 infection 77 73 ( 94 . 8 ) 92 . 8 ( 88 . 3 - 96 . 1 ) 6 ( 100 . 0 ) - 10 ( 90 . 9 ) - 74 ( 96 . 1 ) 94 . 3 ( 90 . 4 - 97 . 1 ) Vaccinated , no booster , and 2022 infection 93 88 ( 94 . 6 ) 92 . 5 ( 88 . 0 - 96 . 0 ) 4 ( 100 . 0 ) - 9 ( 100 . 0 ) - 91 ( 97 . 8 ) 93 . 3 ( 89 . 1 - 96 . 4 ) Vaccinated , booster , and uninfected 224 203 ( 90 . 6 ) 93 . 1 ( 89 . 4 - 96 . 2 ) 23 ( 100 . 0 ) - 45 ( 93 . 8 ) - 219 ( 97 . 8 ) 98 . 0 ( 96 . 1 - 99 . 3 ) Vaccinated , booster , and pre - 2022 infection 73 72 ( 98 . 6 ) 99 . 3 ( 98 . 6 - 99 . 7 ) 6 ( 100 . 0 ) - 12 ( 100 . 0 ) - 73 ( 100 . 0 ) 99 . 7 ( 99 . 2 - 99 . 9 ) Vaccinated , booster , and 2022 infection 104 102 ( 98 . 1 ) 99 . 2 ( 98 . 4 - 99 . 7 ) 13 ( 100 . 0 ) - 26 ( 100 . 0 ) - 103 ( 99 . 0 ) 99 . 6 ( 99 . 0 - 99 . 9 ) a Number and proportion ( % ) above the threshold for neutralizing activity against specific variant . b Estimated seroprevalence % ( 95 % credible interval ) of neutralizing antibodies against specific variant , from regression model accounting for age , sex , self - reported most recent SARS - CoV - 2 infection and vaccination status , and post - stratifying to the demographic and vaccination and infection statuses of the Geneva general population . c Self - reported vaccination and most recent infection via a COVID - 19 diagnostic positive test ( RT - PCR or rapid antigen test , including self - test ) . The cell - free surrogate neutralization assay can be multiplexed to test up to ten variants on the same sample . For logistics reasons , numbers of tested samples per variant were as follows : N = 1160 for D614G , Alpha , Beta , Gamma , Delta , Lambda , Omicron BA . 1 , and Omicron BA . 2 ; N = 1078 for Omicron BA . 4 / BA . 5 ; N = 995 for Omicron BA . 2 . 12 . 1 ; N = 165 for Kappa ; and N = 82 for Iota . 27 Table S7 continued . Seroprevalence estimates of neutralizing anti - SARS - CoV - 2 antibodies against main variants in the general population of Geneva , Switzerland , April 29 th to June 9 th , 2022 SARS - CoV - 2 variant Omicron BA . 1 Omicron BA . 2 Omicron BA . 2 . 12 . 1 Omicron BA . 4 / BA . 5 n n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) b n ( % ) a Seroprevalence % ( 95 % CrI ) b Total 1160 587 ( 50 . 6 ) 52 . 3 ( 48 . 9 - 55 . 8 ) 640 ( 55 . 2 ) 56 . 3 ( 52 . 8 - 59 . 8 ) 455 ( 45 . 7 ) 47 . 5 ( 43 . 6 - 51 . 3 ) 486 ( 45 . 1 ) 46 . 7 ( 43 . 0 - 50 . 4 ) Men 327 ( 51 . 8 ) 52 . 7 ( 48 . 6 - 56 . 9 ) 358 ( 56 . 7 ) 57 . 1 ( 52 . 8 - 61 . 6 ) 251 ( 46 . 8 ) 47 . 8 ( 42 . 9 - 52 . 5 ) 269 ( 45 . 9 ) 46 . 3 ( 41 . 6 - 50 . 7 ) Women 260 ( 49 . 1 ) 52 . 0 ( 47 . 4 - 56 . 4 ) 282 ( 53 . 3 ) 55 . 5 ( 50 . 8 - 60 . 2 ) 204 ( 44 . 4 ) 47 . 2 ( 42 . 3 - 52 . 1 ) 217 ( 44 . 1 ) 47 . 1 ( 42 . 5 - 51 . 8 ) Age group , y 0 - 5 91 19 ( 20 . 9 ) 26 . 3 ( 16 . 4 - 36 . 7 ) 17 ( 18 . 7 ) 21 . 1 ( 11 . 7 - 31 . 6 ) 9 ( 9 . 9 ) 11 . 5 ( 5 . 0 - 20 . 1 ) 9 ( 9 . 9 ) 11 . 5 ( 4 . 7 - 20 . 2 ) 6 - 11 128 26 ( 20 . 3 ) 21 . 9 ( 14 . 6 - 30 . 3 ) 30 ( 23 . 4 ) 23 . 9 ( 15 . 6 - 32 . 4 ) 25 ( 19 . 5 ) 19 . 3 ( 11 . 7 - 27 . 5 ) 23 ( 18 . 0 ) 17 . 3 ( 9 . 8 - 25 . 5 ) 12 - 17 109 65 ( 59 . 6 ) 54 . 2 ( 45 . 0 - 63 . 7 ) 70 ( 64 . 2 ) 59 . 1 ( 49 . 8 - 68 . 2 ) 63 ( 57 . 8 ) 51 . 7 ( 42 . 0 - 61 . 1 ) 60 ( 55 . 0 ) 48 . 2 ( 39 . 1 - 57 . 7 ) 18 - 24 95 69 ( 72 . 6 ) 63 . 8 ( 53 . 6 - 74 . 7 ) 75 ( 78 . 9 ) 69 . 7 ( 59 . 2 - 80 . 1 ) 55 ( 64 . 0 ) 54 . 3 ( 43 . 6 - 65 . 1 ) 57 ( 63 . 3 ) 53 . 2 ( 43 . 0 - 63 . 6 ) 25 - 34 128 84 ( 65 . 6 ) 59 . 0 ( 50 . 8 - 67 . 6 ) 93 ( 72 . 7 ) 64 . 5 ( 56 . 1 - 72 . 4 ) 65 ( 63 . 1 ) 55 . 0 ( 45 . 9 - 64 . 0 ) 67 ( 59 . 3 ) 52 . 7 ( 44 . 4 - 61 . 2 ) 35 - 49 192 105 ( 54 . 7 ) 56 . 3 ( 50 . 5 - 62 . 1 ) 116 ( 60 . 4 ) 60 . 2 ( 54 . 0 - 66 . 1 ) 83 ( 52 . 5 ) 53 . 3 ( 47 . 2 - 59 . 5 ) 97 ( 55 . 1 ) 54 . 9 ( 48 . 8 - 61 . 2 ) 50 - 64 193 104 ( 53 . 9 ) 56 . 3 ( 49 . 6 - 62 . 9 ) 116 ( 60 . 1 ) 62 . 5 ( 55 . 9 - 69 . 0 ) 76 ( 50 . 3 ) 51 . 7 ( 43 . 9 - 59 . 2 ) 87 ( 49 . 4 ) 51 . 4 ( 44 . 4 - 58 . 6 ) 65 - 74 117 60 ( 51 . 3 ) 49 . 3 ( 41 . 1 - 57 . 5 ) 66 ( 56 . 4 ) 54 . 1 ( 45 . 8 - 62 . 3 ) 39 ( 44 . 8 ) 43 . 0 ( 34 . 3 - 52 . 6 ) 43 ( 43 . 4 ) 42 . 0 ( 33 . 1 - 51 . 2 ) ‚â•75 107 55 ( 51 . 4 ) 54 . 3 ( 45 . 5 - 63 . 5 ) 57 ( 53 . 3 ) 55 . 8 ( 46 . 7 - 64 . 6 ) 40 ( 48 . 8 ) 52 . 4 ( 42 . 3 - 62 . 8 ) 43 ( 44 . 8 ) 49 . 7 ( 40 . 5 - 59 . 3 ) Vaccination and infection status c Unvaccinated and uninfected 39 0 ( 0 . 0 ) 2 . 4 ( 1 . 2 - 4 . 2 ) 1 ( 2 . 6 ) 2 . 9 ( 1 . 3 - 5 . 1 ) 0 ( 0 . 0 ) 1 . 8 ( 0 . 8 - 3 . 3 ) 0 ( 0 . 0 ) 1 . 5 ( 0 . 6 - 2 . 8 ) Unvaccinated and pre - 2022 infection 55 12 ( 21 . 8 ) 13 . 3 ( 7 . 8 - 19 . 9 ) 15 ( 27 . 3 ) 16 . 5 ( 9 . 8 - 24 . 5 ) 12 ( 22 . 6 ) 9 . 7 ( 4 . 8 - 15 . 8 ) 10 ( 18 . 2 ) 8 . 5 ( 4 . 1 - 13 . 7 ) Unvaccinated and 2022 infection 94 29 ( 30 . 9 ) 38 . 0 ( 29 . 8 - 46 . 5 ) 24 ( 25 . 5 ) 37 . 2 ( 28 . 5 - 45 . 2 ) 18 ( 20 . 0 ) 26 . 1 ( 17 . 8 - 34 . 4 ) 17 ( 18 . 7 ) 23 . 6 ( 15 . 5 - 31 . 5 ) Vaccinated , no booster , and uninfected 54 6 ( 11 . 1 ) 23 . 5 ( 16 . 1 - 31 . 4 ) 10 ( 18 . 5 ) 30 . 8 ( 22 . 1 - 40 . 0 ) 6 ( 12 . 8 ) 24 . 2 ( 16 . 4 - 32 . 9 ) 7 ( 13 . 5 ) 23 . 8 ( 16 . 3 - 32 . 1 ) Vaccinated , no booster , and pre - 2022 infection 77 44 ( 57 . 1 ) 58 . 1 ( 48 . 7 - 67 . 3 ) 48 ( 62 . 3 ) 64 . 7 ( 54 . 8 - 74 . 1 ) 34 ( 51 . 5 ) 53 . 2 ( 42 . 7 - 63 . 6 ) 38 ( 53 . 5 ) 55 . 1 ( 45 . 0 - 65 . 1 ) Vaccinated , no booster , and 2022 infection 93 81 ( 87 . 1 ) 85 . 8 ( 79 . 7 - 91 . 0 ) 84 ( 90 . 3 ) 86 . 5 ( 80 . 9 - 91 . 6 ) 68 ( 81 . 0 ) 81 . 4 ( 74 . 4 - 87 . 8 ) 71 ( 79 . 8 ) 82 . 5 ( 75 . 8 - 88 . 4 ) Vaccinated , booster , and uninfected 224 73 ( 32 . 6 ) 38 . 9 ( 32 . 9 - 45 . 2 ) 95 ( 42 . 4 ) 49 . 2 ( 42 . 6 - 55 . 4 ) 54 ( 30 . 7 ) 36 . 5 ( 29 . 6 - 44 . 1 ) 56 ( 27 . 9 ) 33 . 7 ( 27 . 2 - 40 . 4 ) Vaccinated , booster , and pre - 2022 infection 73 51 ( 69 . 9 ) 76 . 8 ( 68 . 3 - 84 . 6 ) 57 ( 78 . 1 ) 83 . 0 ( 75 . 6 - 89 . 4 ) 38 ( 62 . 3 ) 70 . 2 ( 60 . 5 - 79 . 2 ) 43 ( 64 . 2 ) 69 . 5 ( 60 . 1 - 78 . 4 ) Vaccinated , booster , and 2022 infection 104 92 ( 88 . 5 ) 93 . 4 ( 89 . 8 - 96 . 3 ) 95 ( 91 . 3 ) 94 . 2 ( 91 . 0 - 96 . 7 ) 67 ( 85 . 9 ) 89 . 6 ( 84 . 8 - 93 . 8 ) 76 ( 83 . 5 ) 89 . 1 ( 84 . 2 - 93 . 3 ) a Number and proportion ( % ) above the threshold for neutralizing activity against specific variant . b Estimated seroprevalence % ( 95 % credible interval ) of neutralizing antibodies against specific variant , from regression model accounting for age , sex , self - reported most recent SARS - CoV - 2 infection and vaccination status , and post - stratifying to the demographic and vaccination and infection statuses of the Geneva general population . c Self - reported vaccination and most recent infection via a COVID - 19 diagnostic positive test ( RT - PCR or rapid antigen test , including self - test ) . The cell - free surrogate neutralization assay can be multiplexed to test up to ten variants on the same sample . For logistics reasons , numbers of tested samples per variant were as follows : N = 1160 for D614G , Alpha , Beta , Gamma , Delta , Lambda , Omicron BA . 1 , and Omicron BA . 2 ; N = 1078 for Omicron BA . 4 / BA . 5 ; N = 995 for Omicron BA . 2 . 12 . 1 ; N = 165 for Kappa ; and N = 82 for Iota . 28 Table S8 . Comparison of seroprevalence of anti - SARS - CoV - 2 antibodies developed through infection by June - July 2021 and April - June 2022 , Geneva , Switzerland Seroprevalence of antibodies after infection % Geneva population N Jun - Jul 2021 serosurvey Apr - Jun 2022 serosurvey Percent increase Absolute increase % points Absolute increase N Total 511921 29 . 9 72 . 4 142 % 42 . 5 216229 Men 248170 30 . 4 71 . 7 136 % 41 . 3 101869 Women 263751 29 . 5 73 . 1 148 % 43 . 6 114284 Age , y 0 - 5 30840 20 . 8 76 . 7 268 % 55 . 8 17093 6 - 11 32382 31 . 4 90 . 5 189 % 59 . 5 19064 12 - 17 32377 37 . 7 86 . 4 129 % 48 . 8 15482 18 - 24 41899 41 . 8 84 . 0 101 % 42 . 3 17835 25 - 34 73273 31 . 9 78 . 9 148 % 47 . 1 34517 35 - 49 115343 32 . 2 74 . 4 131 % 42 . 2 48646 50 - 64 100883 29 . 8 67 . 7 127 % 37 . 9 37840 65 - 74 40143 22 . 5 55 . 0 144 % 32 . 5 13103 ‚â•75 44781 16 . 2 45 . 9 182 % 29 . 5 12831 Percent increase calculated as : ( ( Apr - Jun 2022 seroprevalence / Jun - Jul 2021 seroprevalence ) ‚Äì 1 ) x 100 . Absolute increase calculated as : Apr - Jun 2022 seroprevalence ‚Äì Jun - Jul 2021 seroprevalence . Absolute increase N calculated as : absolute increase % x Geneva population Seroprevalence estimates for Jun - Jul 2021 from previous seroprevalence study . 3 Data on Geneva population available from : https : / / www . ge . ch / statistique / domaines / 01 / 01 _ 01 / tableaux . asp # 5 29 References 1 Stringhini S , Wisniak A , Piumatti G , et al . Seroprevalence of anti - SARS - CoV - 2 IgG antibodies in Geneva , Switzerland ( SEROCoV - POP ) : a population - based study . The Lancet 2020 ; 396 : 313 ‚Äì 9 . 2 Stringhini S , Zaballa M - E , Perez - Saez J , et al . Seroprevalence of anti - SARS - CoV - 2 antibodies after the second pandemic peak . The Lancet Infectious Diseases 2021 ; 21 : 600 ‚Äì 1 . 3 Stringhini S , Zaballa M - E , Pullen N , et al . Seroprevalence of anti - SARS - CoV - 2 antibodies 6 months into the vaccination campaign in Geneva , Switzerland , 1 June to 7 July 2021 . Eurosurveillance 2021 ; 26 : 2100830 . 4 Baden LR , El Sahly HM , Essink B , et al . Efficacy and Safety of the mRNA - 1273 SARS - CoV - 2 Vaccine . N Engl J Med 2020 ; 384 : 403 ‚Äì 16 . 5 Polack FP , Thomas SJ , Kitchin N , et al . Safety and Efficacy of the BNT162b2 mRNA Covid - 19 Vaccine . N Engl J Med 2020 ; 383 : 2603 ‚Äì 15 . 6 Bos R , Rutten L , van der Lubbe JEM , et al . Ad26 vector - based COVID - 19 vaccine encoding a prefusion - stabilized SARS - CoV - 2 Spike immunogen induces potent humoral and cellular immune responses . npj Vaccines 2020 ; 5 : 1 ‚Äì 11 . 7 Muench P , Jochum S , Wenderoth V , et al . Development and Validation of the Elecsys Anti - SARS - CoV - 2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS - CoV - 2 . Journal of Clinical Microbiology 2020 ; 58 : e01694 - 20 . 8 Ainsworth M , Andersson M , Auckland K , et al . Performance characteristics of five immunoassays for SARS - CoV - 2 : a head - to - head benchmark comparison . The Lancet Infectious Diseases 2020 ; 20 : 1390 ‚Äì 400 . 9 Stan Development Team . Stan Modeling Language Users Guide and Reference Manual . Version 2 . 21 . 0 . 2019 . https : / / mc - stan . org . 10 Stan Development Team . Rstan : the R interface to Stan . R package version 2 . 21 . 2 . 2020 . https : / / mc - stan . org . 11 R Core Team . R : A Language and Environment for Statistical Computing . Vienna , Austria , 2021 https : / / www . R - project . org / . 12 Gabry J . shinystan : Interactive Visual and Numerical Diagnostics and Posterior Analysis for Bayesian Models . R package version 2 . 5 . 0 . . 13 Fenwick C , Turelli P , Pellaton C , et al . A high - throughput cell - and virus - free assay shows reduced neutralization of SARS - CoV - 2 variants by COVID - 19 convalescent plasma . Sci Transl Med 2021 ; 13 : eabi8452 . 14 Vehtari A , Gelman A , Gabry J . Practical Bayesian model evaluation using leave - one - out cross - validation and WAIC . Stat Comput 2017 ; 27 : 1413 ‚Äì 32 . 15 Vehtari A , Gabry J , Yao Y , Gelman A . Loo : Efficient Leave - One - Out Cross - Validation and WAIC for Bayesian Models . 2018 .